Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Akshay Vaishnaw
AddedFeb 19, 2024
UpdatedMay 31, 2026
Akshay Vaishnaw

Akshay Vaishnaw

Board Member, Scholar Rock Holding

LinkedInThe Org

Akshay Vaishnaw's Career

Scholar Rock Holding
Scholar Rock Holding

Cambridge, MA, US

Board Member· Board
Editas Medicine
Editas Medicine

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Akshay Vaishnaw's Career

Scholar Rock Holding
Scholar Rock Holding
Public1142017Cambridge, MA, US
Board Member· Board

Leadership at Scholar Rock Holding

Jay BackstromJay BackstromCEO
David HallalDavid HallalBoard Member
Joshua ReedJoshua ReedBoard Member
Srinivas AkkarajuSrinivas AkkarajuBoard Member
Amir NashatAmir NashatBoard Member
Kristina BurowKristina BurowBoard Member

Similar to Scholar Rock Holding

Fulcrum TherapeuticsFulcrum TherapeuticsCambridge, MA, USPharmaceuticalsest. 2016Fulcrum TherapeuticsCambridge, MA, US · est. 2016

Fulcrum Therapeutics, Inc., a Cambridge-based company, develops and distributes transformative gene regulation drugs.

Public · $603.3M89
Solid BiosciencesSolid BiosciencesCambridge, MA, USGene Therapy, Therapiesest. 2013Solid BiosciencesCambridge, MA, US · est. 2013

Solid Biosciences Inc., a US-based biotech firm, develops therapies and devices for muscular dystrophy.

Public · $441.3M87
Blueprint MedicinesBlueprint MedicinesCambridge, MA, USCancer Treatmentsest. 2008Blueprint MedicinesCambridge, MA, US · est. 2008

Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.

Public · $2.4B641
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
Editas Medicine
Editas Medicine
Public$931.6M2262013Cambridge, MA, US
Board Member· Board

Leadership at Editas Medicine

J. Keith JoungJ. Keith JoungBoard Member
George ChurchGeorge ChurchBoard Member
David R. LiuDavid R. LiuBoard Member
Gilmore O’NeillGilmore O’NeillBoard Member
Feng ZhangFeng ZhangBoard Member
Meeta ChatterjeeMeeta ChatterjeeBoard Member

Akshay Vaishnaw's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Akshay Vaishnaw

YVONNE GREENSTREETYVONNE GREENSTREETCEO · Alnylam Pharmaceuticals alnYvonne GreenstreetYvonne GreenstreetCEO · Alnylam Pharmaceuticals alnMarshall ThompsonMarshall ThompsonFounder · CanworksEmma ReeveEmma ReeveBoard Member · Whitehawk TherapeuticsAmrit RayAmrit RayBoard Member · Ultragenyx Pharmaceutical